Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach
Journal of Chemical Information and Modeling · 2023
DOI: 10.1021/acs.jcim.3c01269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, 2023. Verfasst von Brandon Havranek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania 19107, United States. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIMHD NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
The COVID-19 pandemic has emphasized the urgency for effective antiviral therapies against SARS-CoV-2. Targeting the main protease (3CLpro) of the virus has emerged as a promising approach, and nirmatrelvir (PF-07321332), the active component of Pfizer's oral drug Paxlovid, has demonstrated remarkable clinical efficacy. However, the emergence of resistance mutations poses a challenge to its continued success. In this study, we employed alchemical free energy perturbation (FEP) alanine scanning to identify nirmatrelvir-resistance mutations within SARS-CoV-2 3CLpro. FEP identified several mutations, which were validated through in vitro IC50 experiments and found to result in 8- and 72-fold increases in nirmatrelvir IC50 values. Additionally, we constructed SARS-CoV-2 omicron replicons containing these mutations, and one of the mutants (S144A/E166A) displayed a 20-fold increase in EC50, confirming the role of FEP in identifying drug-resistance mutations. Our findings suggest that FEP can be a valuable tool in proactively monitoring the emergence of resistant strains and guiding the design of future inhibitors with reduced susceptibility to drug resistance. As nirmatrelvir is currently widely used for treating COVID-19, this research has important implications for surveillance efforts and antiviral development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania 19107, United States.
- ComputePharma, LLC, Chicago, Illinois 60607, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60607, United States.
- Biophysics Core at Research Resource Center, University of Illinois at Chicago, Chicago, Illinois 60607, United States.
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
- Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
ORCID-Profile: Brandon Havranek, Hyun Lee, Anoklase Jean-Luc Ayitou, Shahidul M Islam
Förderung
- NIGMS NIH HHS
- NIMHD NIH HHS
- NCATS NIH HHS
- National Institute on Minority Health and Health Disparities
- National Institute of General Medical Sciences
- Center for Clinical and Translational Science, University of Illinois at Chicago
- Division of Materials Research
Zitieren
APA
Havranek, B., Demissie, R., Lee, H., Lan, S., Zhang, H., Sarafianos, S., Ayitou, A. J., & Islam, S. M. (2023). Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.3c01269
Vancouver
Havranek B, Demissie R, Lee H, Lan S, Zhang H, Sarafianos S, et al. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach. Journal of Chemical Information and Modeling. 2023. doi:10.1021/acs.jcim.3c01269
BibTeX
@article{Havranek2023,
author = {Havranek, Brandon and Demissie, Robel and Lee, Hyun and Lan, Shuiyun and Zhang, Huanchun and Sarafianos, Stefanos and Ayitou, Anoklase Jean-Luc and Islam, Shahidul M},
title = {Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach},
journal = {Journal of Chemical Information and Modeling},
year = {2023},
doi = {10.1021/acs.jcim.3c01269}
}
EUVIMED